Onset: Mood effects begin at 1-2 weeks, faster than typical SSRIs (4-6 weeks). Joint-pain effects begin at 1-2 weeks, slower than NSAIDs (24-72 hours) but comparable end-state by week 4-8. Most users describe a "lift" rather than the flatter affect SSRIs produce.

At therapeutic dose (400-1,600 mg/day, enteric coated, on empty stomach):

• Mood: Subjective "lift" — interest, motivation, drive return. Less anhedonia. Some users describe a quality similar to bupropion (catecholaminergic activation) more than SSRI (serotonergic flattening).
• Energy: Mild stimulant-like activation in many users. Best taken AM for this reason — evening dosing can disrupt sleep onset.
• Joint comfort: For OA users, gradual reduction in pain and stiffness — slower than NSAID/COX-2 onset but cumulative benefit by week 4-8.
• Mental clarity: Mixed reports. Some users report improved focus; others report a "wired" or jittery quality at higher doses (>800 mg single dose).
• Sleep: Variable. Most users tolerate AM dosing without sleep disruption. Evening dosing or split AM+midday dosing in sensitive users.

Activation / anxiety subset (~10-20% of users):

• Increased catecholamine signaling can produce restlessness, anxiety, agitation, palpitations — usually within 1-3 days of starting.
• Often resolves with dose reduction (start at 200 mg, titrate); some users do not tolerate it at any dose.
• This is the SAM-e equivalent of the "SSRI activation" warning — possibly more common with SAM-e because of the more direct catecholaminergic effect.

Tolerance trajectory:

• Most clinical and anecdotal reports describe stable response over months — tolerance is not a prominent feature.
• A subset of users describe "burnout" at 6-12 months — possibly from methyl-cycle depletion of cofactors (B12, folate, B6) if not co-supplemented.

Discontinuation:

• Typically smooth — no documented withdrawal syndrome. Mood may regress to baseline over 2-4 weeks.
• Bipolar individuals discontinuing during a mania episode require psychiatric management of the mania, not gradual taper of SAM-e itself.

• Tolerance buildup: minimal at therapeutic doses for depression and OA. Most clinical trials maintain stable response over 6-12 months without dose escalation.
• Cycling: not strictly required. Continuous use is standard. Some practitioners cycle 3 months on / 1 month off as a "methylation reset," but this is not evidence-based.
• Reset protocol: If subjective response wanes after 6-12 months, check B12, folate, homocysteine, TSH, vitamin D, and sleep quality before escalating dose. Often "burnout" is a depleted cofactor problem, not a SAM-e tolerance problem.
• Cross-tolerance: None established. SAM-e operates upstream of monoamine systems rather than directly at receptors, so doesn't cross-tolerate with SSRIs, NDRIs, or stimulants in the conventional sense.

Synergistic

• Methyl-B12 (methylcobalamin) + methyl-folate (5-MTHF): Essential co-supplements. Prevent paradoxical homocysteine elevation. The MTHF + methyl-B12 + SAM-e triad is the foundational methylation stack.
• P5P (pyridoxal-5-phosphate / active B6): Required for transsulfuration arm — clears homocysteine via cystathionine β-synthase. Especially relevant in CBS variants.
• TMG (trimethylglycine / betaine): Alternative methyl donor and homocysteine remethylation pathway (BHMT). Synergistic for methylation support; particularly useful in MTHFR carriers.
• TUDCA (tauroursodeoxycholic acid): Synergistic for liver protection — different mechanism (bile-acid signaling vs methyl donation). Standard stack for oral anabolic steroid users.
• Omega-3 (EPA/DHA): Independent antidepressant effects + methylation-supportive (DHA is a substrate for SAM-e-dependent methylation in neuronal membranes). Adjunctive in depression context.
• Magnesium: Cofactor for ATP regeneration → methionine adenosyltransferase activity. Generic supportive role.
• L-theanine: Counters the activation/anxiety subset effect for users who get jittery on SAM-e. Anecdotal but well-tolerated.

Avoid stacking with

• SSRIs / SNRIs / MAOIs / tramadol / triptans / St. John's Wort / 5-HTP at high dose: Serotonin syndrome risk. Medical supervision required.
• Levodopa (without carbidopa adjustment): SAM-e can methylate L-dopa via COMT, reducing efficacy. Parkinson's patients on L-dopa need physician oversight.
• Niacin (large doses, >500 mg): Niacin is a methyl-group sink (NNMT converts nicotinamide to N-methylnicotinamide using SAM-e). High-dose niacin can deplete SAM-e — counterproductive.
• MAOI-B inhibitors (selegiline): Methylation pathway interactions; possible serotonin syndrome risk.

Neutral co-administration

• Creatine, omega-3, vitamin D3, magnesium, zinc, NAC — no known antagonism, several mechanistic synergies via methylation support or shared mood/recovery pathways.
• Community data shows L-theanine, vitamin D3, L-tyrosine, rhodiola, NAC, omega-3 as the top six co-administered supplements — consistent with a mood/cognition/recovery cluster.

• CYP450: SAM-e is not a significant CYP450 substrate, inducer, or inhibitor at therapeutic doses. Drug-drug interactions are pharmacodynamic (serotonergic) rather than pharmacokinetic.
• Antidepressants (SSRI, SNRI, TCA, MAOI, tramadol, triptans): Serotonin syndrome risk — medical supervision required. Symptoms: tremor, hyperreflexia, clonus, agitation, hyperthermia, autonomic instability. Onset hours to days.
• Levodopa: SAM-e can reduce L-dopa efficacy via increased COMT methylation. Carbidopa partially mitigates. Parkinson's specialists should oversee.
• MAOIs (including selegiline, rasagiline, moclobemide): Combined risk of serotonin syndrome and hypertensive reactions; avoid without supervision.
• Anticoagulants (warfarin): No documented direct interaction; theoretical concern via altered homocysteine and platelet methylation. Monitor INR if combining.
• Hormonal contraceptives: Estrogen modulates methionine cycle (boosts MTHFR activity). No direct interaction with SAM-e absorption or excretion. Possible reduced subjective response in women on combined hormonal contraceptives (consistent with Sarris 2015 male-superior response).
• Alcohol: No acute interaction, but chronic alcohol depletes methionine cycle cofactors. SAM-e is sometimes used adjunctively in alcoholic liver disease, but does not mitigate ethanol's CNS effects or addiction trajectory.
• NSAIDs: No direct interaction — SAM-e can substitute for NSAIDs in OA without GI ulceration risk.

SAM-e response and metabolism are among the most pharmacogenomically interpretable supplements:

• MTHFR C677T (rs1801133): Reduced enzyme activity in CT (heterozygous, ~40% of European-descent population) and especially TT (homozygous, ~10%). TT carriers have ~30% endogenous MTHFR activity, elevated homocysteine if folate intake low, and theoretically enhanced response to exogenous SAM-e or methyl-folate. For Dylan: 23andMe ordered 2026-04-30 will return this; results window early-mid June 2026. If TT or CT with elevated homocysteine on bloodwork → methyl-folate first, SAM-e if homocysteine remains elevated.
• MTHFR A1298C (rs1801131): Less functionally consequential than C677T in isolation. Compound heterozygotes (677CT + 1298AC) show intermediate phenotype.
• COMT Val158Met (rs4680): Val/Val ("warriors") = high COMT activity = faster catecholamine clearance = less affected by SAM-e-driven methylation. Met/Met ("worriers") = low COMT activity = slower clearance = potentially more sensitive to SAM-e-induced catecholamine effects (both benefit and side-effect-wise). Met/Met carriers may need lower starting doses.
• MAT1A variants: Affect endogenous SAM-e synthesis. Severe deficiency presents in pediatric metabolic medicine; subclinical variants exist but not commonly tested.
• CBS (cystathionine β-synthase) variants: Affect homocysteine clearance via transsulfuration. Relevant for monitoring homocysteine response to SAM-e.
• MTR / MTRR (methionine synthase, methionine synthase reductase): B12-dependent homocysteine remethylation. Reduced activity → more homocysteine accumulation under SAM-e load → cofactor support more important.

Practical PGx workflow for the user archetype: Wait for 23andMe (June 2026). If MTHFR TT or compound heterozygote + homocysteine >10 μmol/L → start with methyl-folate 800-1,600 μg + methyl-B12 1,000-5,000 μg. Recheck homocysteine at 12 weeks. If still elevated, add SAM-e 200-400 mg AM. If MTHFR wild-type and homocysteine <10 — SAM-e provides no methylation benefit; only consider for mood or joint indications.

Cost estimate at therapeutic dose:

• 400 mg/day: ~$30-40/month
• 800 mg/day: ~$50-70/month
• 1,200 mg/day: ~$75-100/month
• 1,600 mg/day: ~$100-140/month

Sourcing-difficulty rating: easy. SAM-e is OTC in the US, widely stocked at Whole Foods, Costco, Amazon, iHerb, Vitacost, supplement specialists. Quality variation exists but the top 5 brands (Jarrow, Doctor's Best, Nature Made, Now Foods, Solgar) are reliable. The constraint is cost, not access.

Baseline / pre-supplementation:

• Homocysteine (plasma) — optimal <7 μmol/L; cardiovascular-relevant ≥10 μmol/L; elevated ≥15 μmol/L. Defines whether methylation support is indicated.
• B12 (serum + methylmalonic acid if borderline) — ≥400 pg/mL preferred; MMA <0.27 μmol/L
• Folate (serum or RBC folate) — RBC folate ≥400 nmol/L preferred
• B6 (plasma PLP) — adequate >20 nmol/L
• ALT, AST, GGT — liver baseline if hepatic indication
• Depression rating (PHQ-9, HAM-D) — baseline severity for mood indication
• Joint pain VAS / WOMAC index — baseline severity for OA indication
• MTHFR genotype (C677T + A1298C) — from 23andMe or direct PGx test
• COMT Val158Met — useful for dose sensitivity prediction

On-supplementation monitoring:

• Homocysteine at 12 weeks — should fall if MTHFR carrier; check cofactor status if rises paradoxically
• PHQ-9 at 4 and 8 weeks — depression response
• Joint pain VAS biweekly — OA response (slower trajectory)
• ALT/AST at 6-8 weeks — confirm liver-protective effect or rule out idiosyncratic hepatic reaction
• Subjective mood/sleep/activation log — daily for first 2 weeks (catch hypomania, activation, anxiety)
• Resting HR + BP — catecholaminergic activation can mildly elevate

For the user archetype (Dylan): Pre-bloodwork (June 2026) — capture homocysteine, B12, folate, MTHFR. If all favorable and no mood/joint indication, SAM-e stays as situational reserve, not daily.